Largest real-world evidence study on Heavy Menstrual Bleeding using OMOP methodology performed across IQVIA and pharma’s own databases

2 Pages

IQVIA conducted the largest RWE study on heavy menstrual bleeding (HMB) across five data sources in four countries using the OMOP framework. The study analyzed treatment pathways of women diagnosed with HMB (2000–2020), finding low diagnosis and delayed treatment despite guideline-recommended LNG-IUDs. Results showed significant variation in treatment across countries and frequent under-treatment. IQVIA developed reusable analytics packages, enabling the client to replicate studies across databases and publish high-impact findings that inform care gaps and policy.

Join for free to read

Report Software + Tech Marketing In The Real World

White Paper Generating evidence for digital health solutions

White Paper Real-world data: The growth guide for biotech and pharma

Case Study SNOWFLAKE & THE EVIDENCE CLOUD

More from IQVIA

Vendor Sheet OMOP Myth Busters

Case Study Label Expansion Supported by a Real-World Evidence (RWE) Study

Vendor Sheet IQVIA MedTech Real World Solutions

White Paper Making Real-World Evidence Meaningful and Actionable

Case Study

Largest real-world evidence study on Heavy Menstrual Bleeding using OMOP methodology performed across IQVIA and pharma’s own databases

Largest real-world evidence study on Heavy Menstrual Bleeding using OMOP methodology performed across IQVIA and pharma’s own databases

You Might Also Like

More from IQVIA